Motion · S2M-02602 · 16 Mar 2005
Treatment of Alzheimer's Disease
The motion
That the Parliament notes with concern the preliminary recommendations of the National Institute for Clinical Excellence (NICE) which, while recognising the effectiveness of three dementia drugs, donepezil, rivastigmine and galantamine, to many sufferers, recommends withdrawing these drugs on the grounds of cost to the NHS in England and Wales; endorses the call by Alzheimer Scotland that all patients with Alzheimer’s disease who are considered suitable by their doctors for these treatments should receive them until it can be shown that either they are not or are no longer benefiting, and considers that the Scottish Executive should ensure that the NICE recommendations are not adopted by NHS Scotland to avoid a disastrous decision for the 62,000 sufferers of dementia in Scotland and their families.
Supporters (19)
- Brian Adam 17 Mar 2005
- Frances Curran 17 Mar 2005
- Rob Gibson 17 Mar 2005
- Carolyn Leckie 17 Mar 2005
- Tricia Marwick 17 Mar 2005
- Alex Neil 17 Mar 2005
- Tommy Sheridan 17 Mar 2005
- Stewart Stevenson 17 Mar 2005
- Sandra White 17 Mar 2005
- Mr David Davidson 18 Mar 2005
- Christine Grahame 18 Mar 2005
- Murray Tosh 18 Mar 2005
- Dr Jean Turner 18 Mar 2005
- Ms Rosemary Byrne 21 Mar 2005
- Dennis Canavan 21 Mar 2005
- Margaret Mitchell 21 Mar 2005
- Donald Gorrie 22 Mar 2005
- Adam Ingram 22 Mar 2005
- Andrew Welsh 23 Mar 2005
Source: the Scottish Parliament motions and amendments record.